Adapting antibodies for clinical use
| Autor: | Robert E. Hawkins, M. B. Llewelyn, Stephen J. Russell |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 1992 |
| Předmět: |
medicine.drug_class
Antibody Affinity Monoclonal antibody Bacteriophage Gene duplication medicine Cytotoxic T cell Humans Technology Pharmaceutical Bacteriophages Gene General Environmental Science biology Immunogenicity General Engineering Antibodies Monoclonal General Medicine biology.organism_classification Virology In vitro Immunology biology.protein General Earth and Planetary Sciences Antibody Genome Bacterial Research Article Forecasting |
| Popis: | Techniques for antibody engineering are now overcoming the problems that have prevented monoclonal antibodies being used routinely in clinical practice. With chemical and genetic manipulation antibodies can be linked to bacterial toxins, enzymes, radionuclides, or cytotoxic drugs, allowing targeting of treatment. Antigen binding sites from antibodies raised in mice can be jointed with human IgG to reduce immunogenicity. In vitro gene amplification and genetic engineering of bacteriophage have produced large antibody gene libraries and facilitated large scale production of human monoclonal antibodies with high specificity. The trickle of monoclonal antibodies into clinical practice may soon become a flood. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|